Therapeutic Effect of Anti-miRNA Mediated by RNA Nanoparticles Targeting CD133 on Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a malignant tumor with a high mortality. Herein, anti-miRNA was investigated for TNBC treatment and explored therapeutic effect was assessed to provide a theoretical basis for treating TNBC. The thermodynamic and chemically stable 3WJ served as a scaffold to construct an RNA nucleic acid ligand that bonded to the CD133 receptor and an LNA sequence containing anti-miRNA21. The constructed nanoparticles were characterized and then applied to TNBC animal models, human breast cancer cells and stem cells (BCSCs), to explore the effect of RNA nanoparticles on TNBC. The study on CD133 aptamers mainly focused on TNBC cells and BCSCs. Results from the study showed specific uptake of nanoparticles. Functional assays showed that treatment with 3WJ/CD133apt/anti-miR21 decreased cell migration and miR21 expression, and increased the expression of PTEN and PDCD, but cytokine secretion did not affect the content of cytokine. Animal experiments proved that the RNA nanoparticles had high targeting of TNBC tumors and had a good suppressive effect on tumor growth. Nanoparticles carrying anti-miR21 could be used an effective treatment method for TNBC. The current study elucidated nanoparticles carrying anti-miR21exerted a significant therapeutic effect on TNBC, helping the development of targeted treatment of TNBC.